Edition:
United Kingdom

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

144.25USD
14 Nov 2018
Change (% chg)

$-0.43 (-0.30%)
Prev Close
$144.68
Open
$145.21
Day's High
$145.31
Day's Low
$143.56
Volume
2,147,235
Avg. Vol
1,992,708
52-wk High
$148.32
52-wk Low
$118.62

Chart for

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $357,562.41
Shares Outstanding(Mil.): 2,684.00
Dividend: 0.84
Yield (%): 2.52

Financials

  JNJ.N Industry Sector
P/E (TTM): 22.53 30.86 33.64
EPS (TTM): 5.91 -- --
ROI: 13.49 14.72 14.22
ROE: 22.63 16.27 15.99

Jury clears J&J of liability in California talc cancer case

A California jury on Wednesday cleared Johnson & Johnson of liability in a case involving a woman who alleged that the company's talc-based products, including its baby powder, contain asbestos and caused her cancer, the company said.

14 Nov 2018

Jury clears J&J of liability in California talc cancer case

A California jury on Wednesday cleared Johnson & Johnson of liability in a case involving a woman who alleged that the company's talc-based products, including its baby powder, contain asbestos and caused her cancer, the company said.

14 Nov 2018

Jury clears J&J of liability in California talc cancer case

Nov 14 A California jury on Wednesday cleared Johnson & Johnson of liability in a case involving a woman who alleged that the company's talc-based products, including its baby powder, contain asbestos and caused her cancer, the company said.

14 Nov 2018

Breakingviews - Private equity could scratch Nestlé skin-care itch

LONDON (Reuters Breakingviews) - Acne and other skin creams have had a spotty record at Nestlé, but a buyout group might do better. A unit at the world’s biggest food group that makes Botox rival Dysport may fetch at least 6 billion Swiss francs ($6 billion). Rival consumer groups may be put off by the business’s products and low margins, but they could appeal to a private equity firm. Facing pressure from activist Dan Loeb, Nestlé Chief Executive Mark Schneider announced a review of the divi

06 Nov 2018

AbbVie lifts profit target after cancer drug powers third-quarter beat

Nov 2 AbbVie Inc beat Wall Street estimates for third-quarter profit and raised its earnings forecast for the year on Friday, driven by strong sales of blockbuster cancer medicine Imbruvica.

02 Nov 2018

Eli Lilly makes bet on gene-silencing drug firm Dicerna

Eli Lilly and Co is spending $100 million for a stake in Dicerna Pharmaceuticals Inc as part of a licensing deal, making it the latest major drugmaker to bet on gene-silencing technology.

29 Oct 2018

Eli Lilly makes bet on gene-silencing drug firm Dicerna

* Lilly to pay Dicerna $100 mln upfront plus $100 mln for stake

29 Oct 2018

Deals of the day-Mergers and acquisitions

Oct 23 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:

23 Oct 2018

J&J makes $2.1 billion offer to buy out Japan cosmetics firm Ci:z

TOKYO U.S. healthcare conglomerate Johnson & Johnson said on Tuesday it will buy all outstanding shares of Japanese skincare firm Ci:z Holdings Co Ltd that it does not already own for 230 billion yen ($2.05 billion) in cash. | Video

23 Oct 2018

Johnson & Johnson makes $2.1 billion offer to buy out Japan cosmetics firm Ci:z

TOKYO U.S. healthcare conglomerate Johnson & Johnson said on Tuesday it will buy all outstanding shares of Japanese skincare firm Ci:z Holdings Co Ltd that it does not already own for 230 billion yen ($2.05 billion) in cash. | Video

23 Oct 2018

Earnings vs. Estimates